Currently however, except in some specific examples such as the BCR-ABL1 fusion in CML, and NPM1 or FLT3 mutations in de novo AML, molecular data are not associated with optimal clinical and therapeutic exploitation in the clinic. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.